A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Lyell Immunopharma, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
Orca Biosystems, Inc.
National Institutes of Health Clinical Center (CC)